A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

por Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I
Publicado 2004

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

por Newell, D R, Burtles, S S, Fox, B W, Jodrell, D I, Connors, T A
Publicado 1999

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

por Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Publicado 1994

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

por Jodrell, D. I., Irvine, A. T., McCready, V. R., Woodcraft, E., Smith, I. E.
Publicado 1988

Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscop...

por Newell, D. R., Maxwell, R. J., Bisset, G. M., Jodrell, D. I., Griffiths, J. R.
Publicado 1990

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

por Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T.
Publicado 2017

The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.

por Jodrell, D. I., Newell, D. R., Morgan, S. E., Clinton, S., Bensted, J. P., Hughes, L. R., Calvert, A. H.
Publicado 1991

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

por Jodrell, D I, Stewart, M, Aird, R, Knowles, G, Bowman, A, Wall, L, Cummings, J, McLean, C
Publicado 2001

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

por Jodrell, D. I., Bowman, A., Stewart, M., Dunlop, N., French, R., MacLellan, A., Cummings, J., Smyth, J. F.
Publicado 1998

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

por Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Publicado 1999

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

por Aird, R E, Cummings, J, Ritchie, A A, Muir, M, Morris, R E, Chen, H, Sadler, P J, Jodrell, D I
Publicado 2002

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

por Jodrell, D. I., Smith, I. E., Mansi, J. L., Pearson, M. C., Walsh, G., Ashley, S., Sinnett, H. D., McKinna, J. A.
Publicado 1991

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

por Lin, Y, Richards, F M, Krippendorff, B-F, Bramhall, J L, Harrington, J A, Bapiro, T E, Robertson, A, Zheleva, D, Jodrell, D I
Publicado 2012

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

por Wong, N A C S, Brett, L, Stewart, M, Leitch, A, Longley, D B, Dunlop, M G, Johnston, P G, Lessells, A M, Jodrell, D I
Publicado 2001

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

por Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Publicado 1998

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

por Bapiro, T E, Frese, K K, Courtin, A, Bramhall, J L, Madhu, B, Cook, N, Neesse, A, Griffiths, J R, Tuveson, D A, Jodrell, D I, Richards, F M
Publicado 2014

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

por Hessmann, E, Patzak, M S, Klein, L, Chen, N, Kari, V, Ramu, I, Bapiro, T E, Frese, K K, Gopinathan, A, Richards, F M, Jodrell, D I, Verbeke, C, Li, X, Heuchel, R, Löhr, J M, Johnsen, S A, Gress, T M, Ellenrieder, V, Neesse, A
Publicado 2018

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

por Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.
Publicado 2020